蓝帆医疗: 第六届董事会第二十九次会议决议公告

Group 1 - The company held its 29th meeting of the 6th Board of Directors on September 4, 2025, via electronic communication, with 7 out of 8 directors participating [1] - The meeting confirmed that the company's stock price had been below 85% of the current conversion price for at least 15 out of the last 30 trading days, triggering the condition for downward adjustment of the "Lanfan Convertible Bond" conversion price [1] Group 2 - To protect the interests of bondholders and optimize the company's capital structure, the Board proposed to lower the conversion price of the "Lanfan Convertible Bond," which requires approval from the shareholders' meeting [2] - The adjusted conversion price will not be lower than the higher of the average stock price over the last 20 trading days before the shareholders' meeting and the previous trading day's stock price, and it must also not be lower than the latest audited net asset value per share and the stock's par value [2] - The Board requested authorization from the shareholders' meeting to handle all matters related to the downward adjustment of the conversion price, including determining the new conversion price and effective date [2] Group 3 - The Board agreed to hold the 2025 Fourth Extraordinary Shareholders' Meeting on September 22, 2025, with unanimous support from the directors [3] - The details of the Board's proposal to adjust the conversion price will be disclosed in designated media outlets [3]